Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
5.2
3.9
Journals
Biomedicines
Special Issues
Feature Reviews in Tumor Immunology
share announcement

Feature Reviews in Tumor Immunology

A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Immunology and Immunotherapy".

Deadline for manuscript submissions: 31 October 2025 | Viewed by 1208

Special Issue Editor

Dr. Maria-Ioanna Christodoulou

E-Mail Website
Guest Editor
1. Department of Life Sciences, European University Cyprus, Nicosia 2404, Cyprus
2. School of Infection and Immunity, University of Glasgow, Glasgow G12 8TA, UK
Interests: tumor immunology; autoimmunity; RNA sequencing; immunotranscriptomics; translational oncology; immunoregulatory cytokines
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

It is now more than five decades since the fields of immunology and oncology were proven to be inextricably linked, overlapping and interacting with each other. From the next generation of hallmarks outlined by Hanahan and Weinberg in Cell in 2011 to the successful routine use of immunotherapies and novel immune strategies in clinical trials, advances in the management of human tumors and improvements in the quality of life of patients have been impressive.

Unravelling the cellular and molecular pathogenetic mechanisms involved in the tumor microenvironment and the activities of immune cell compartments have paved the way for the development of interventions with monoclonal antibodies, immune checkpoint inhibitors, vaccines, cytokines, immunomodulators and CAR-T cells to prevent or inhibit immune escape and enhance anti-tumor immunity.

However, while the data gathered so far form a solid basis for future advances in the field, many questions regarding the optimal management of human malignancies remain. This Special Issue welcomes the submission of recent review articles that address immune-related pathogenetic mechanisms, the cellular and molecular networks underlying human tumors, current, novel and future approaches to their exploration, current and future immunotherapeutics, and ongoing pre-clinical and clinical studies on immunotherapies.

Dr. Maria-Ioanna Christodoulou
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • tumor immunity
  • immunotherapy
  • engineered immune cells
  • antibodies
  • immunomodulators
  • cytokines
  • survival
  • immune-checkpoint inhibitors
  • tumor immune microenvironment

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Review

19 pages, 3261 KiB  
Review
The Role of Tregs in the Tumor Microenvironment
by Yohei Sato
Biomedicines 2025, 13(5), 1173; https://doi.org/10.3390/biomedicines13051173 - 11 May 2025
Viewed by 327
Abstract
The tumor microenvironment (TME) is a unique ecosystem that surrounds tumor tissues. The TME is composed of extracellular matrix, immune cells, blood vessels, stromal cells, and fibroblasts. These environments enhance cancer development, progression, and metastasis. Recent success in immune checkpoint blockade also supports [...] Read more.
The tumor microenvironment (TME) is a unique ecosystem that surrounds tumor tissues. The TME is composed of extracellular matrix, immune cells, blood vessels, stromal cells, and fibroblasts. These environments enhance cancer development, progression, and metastasis. Recent success in immune checkpoint blockade also supports the importance of the TME and immune cells residing in the tumor niche. Although the TME can be identified in almost all cancer types, the role of the TME may not be similar among different cancer types. Regulatory T cells (Tregs) play a pivotal role in immune homeostasis and are frequently found in the TME. Owing to their suppressive function, Tregs are often considered unfavorable factors that allow the immune escape of cancer cells. However, the presence of Tregs is not always linked to an unfavorable phenotype, which can be explained by the heterogeneity and plasticity of Tregs. In this review, the current understanding of the role of Tregs in TME is addressed for each cancer cell type. Moreover, recently a therapeutic approach targeting Tregs infiltrating in the TME has been developed including drug antibody conjugate, immunotoxin, and FOXP3 inhibiting peptide. Thus, understanding the role of Tregs in the TME may lead to the development of novel therapies that directly target the TME. Full article
(This article belongs to the Special Issue Feature Reviews in Tumor Immunology)
►▼ Show Figures

Figure 1

20 pages, 1818 KiB  
Review
Oligodendroglioma: Advances in Molecular Mechanisms and Immunotherapeutic Strategies
by Yongxin Zhao, Yan Yu, Weizhi Chen, Xiaojun Zhang, Jing Lv and Heping Zhao
Biomedicines 2025, 13(5), 1133; https://doi.org/10.3390/biomedicines13051133 - 7 May 2025
Viewed by 248
Abstract
Oligodendroglioma is a central nervous system tumor defined by IDH1/2 mutations and 1p/19q co-deletion. Current management involves maximal resection followed by radiotherapy/chemotherapy, yielding a 20-year survival rate of 37% for grade 3 tumors according to the WHO 2021 classification. As these tumors primarily [...] Read more.
Oligodendroglioma is a central nervous system tumor defined by IDH1/2 mutations and 1p/19q co-deletion. Current management involves maximal resection followed by radiotherapy/chemotherapy, yielding a 20-year survival rate of 37% for grade 3 tumors according to the WHO 2021 classification. As these tumors primarily affect young to middle-aged patients, novel therapies are urgently needed to improve outcomes. Immunotherapy has revolutionized tumor treatment by modulating immune responses. However, its application in oligodendrogliomas faces two major hurdles, including the immunosuppressive tumor microenvironment (TME) and the blood–brain barrier’s restrictive properties. This review first examines oligodendroglioma’s molecular alterations to refine diagnosis and guide targeted therapies. Next, we focus on the oligodendroglioma TME to evaluate emerging immunotherapies, including oncolytic viruses, immune checkpoint blockade, chimeric antigen receptor (CAR) T-cell therapy, and cancer vaccines. Finally, we discuss current challenges and future directions to overcome therapeutic limitations and advance treatment strategies. Full article
(This article belongs to the Special Issue Feature Reviews in Tumor Immunology)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop